Genvor Inc (GNVR) Form 8-K — Oct 26, 2026
On October 22, 2026, Genvor Incorporated entered into an Intellectual Property Assignment Agreement with co-founder and Chief Scientific Officer Dr. Jesse Jaynes, assigning to the company all rights in the synthetic peptide library — including roughly 9,000 antimicrobial peptides — plus associated data, design notes, and the BioCypher AI platform. The agreement was executed in connection with Genvor's proposed underwritten public offering and Nasdaq listing, confirming in writing that the library is company property in all fields, effective back to the original 2010 filing date.
Key figures
- Ip effective date
- 2010-06-19
- Antimicrobial peptides in library
- 9000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.